MiraLax reports strong sales in third quarter 2008
KENILWORTH, N.J. Schering-Plough on Tuesday reported strong results across its MiraLax over-the-counter laxative offering, doubling its retail sales of MiraLax to $31 million for the third quarter ending Sept. 30. “Within just two years of being on the market, OTC Miralax is already a category leader, running neck and neck with Metamucil,” commented Bob Bertolini, Schering-Plough executive vice president and chief financial officer, during an analyst conference call Tuesday morning. Schering-Plough’s consumer healthcare division reached sales of $278 million for the quarter, which is up 2 percent.
Overall, GAAP net sales for the 2008 third quarter totaled $4.6 billion, up 63 percent as compared to the third quarter of 2007, the company reported.
Flavours launches NutraBitz all-natural, probiotic soft chews
CORONA, Calif. Flavours Inc. on Monday announced the introduction of NutraBitz, a line of all-natural, oat-based soft chews containing both prebiotics and probiotics for private label applications.
“Probiotics are one of the hottest market trends today, but right now consumers can’t get them in delivery forms that make taking probiotics enjoyable. NutraBitz changes that,” Flavours Inc. director of sales, Tara Foster, said.
Flavours plans to showcase the new product offering Supply Side West, which is being held Oct. 22-24 in Las Vegas.
According to the company, the idea for NutraBitz was inspired by the continuing emergence of medical research demonstrating the benefits of probiotics in a wide variety of health conditions and growing consumer interest and demand for probiotic alternatives to refrigerated yogurts and probiotic capsules and tablets. “Consumers are now much more aware of the benefits of probiotics and are looking for other ways of getting them into the daily diet,” the company stated.
Each 5.5 gram NutraBitz soft chew is 15-20 calories and contains 1 billion CFU of the GanedenBC30 strain of Bacillus coagulans probiotics.
GlaxoSmithKline and Merix settle extended dispute over advertising practices
CHICAGO According to court documents filed last month, Merix Pharmaceutical and GlaxoSmithKline have settled a three-year dispute over advertising and competition practices for an undisclosed amount. “In exchange for certain consideration, the settlement agreement calls for Merix to dismiss with prejudice its claims against GSK, with each side to bear its own costs, expenses and attorneys’ fees,” the court documents, filed Sept. 2, read.
Merix had filed suit in March 2005 charging that certain advertising claims made by GlaxoSmithKline in support of its cold sore remedies Abreva and Valtrex may be false and misleading, using unreliable test data to promulgate advertising claims in an intentional effort to deceive doctors and the public.